XOMA Royalty Corporation acquires Generation Bio Co. (2025)

Deal facts

Buyer: XOMA Royalty Corporation
Target: Generation Bio Co.
Deal value: Not disclosed
Announced: 15 December 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, earn-out

Sources

SEC_EDGAR_8K SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

2 updates

9 Feb 2026CompletedClosed
XOMA Royalty Corporation completes acquisition of Generation Bio Co.
Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA Royalty ”) entered into an Agreement and Plan of Merger, dated December 15, 2025 (the “ Merger Agreement ”), with Generation Bio Co., a Delaware corporation (the “ Company ” or “ Generation Bio ”), and XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of XOMA Roya
Source
9 Feb 2026CompletedClosed
XOMA Royalty Corporation completes acquisition of Generation Bio Co.
Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on August 2, 2018, Generation Bio Co. (the “Company”) entered into a lease agreement (as subsequently amended, the “Lease”) with BMR-Rogers Street LLC (the “Landlord”), pursuant to which the Company leased approximately 71,562 square feet of research and development, laboratory and office space at 301 Binney Street, Camb
Source

OpinionExit Mode editorial

The completed acquisition of Generation Bio Co by XOMA Royalty Corporation marks a distinct shift in how biotech assets are valued and exited. We see this as a clear signal that public markets are struggling to price the long-term potential of novel gene therapies, pushing founders toward private capital solutions. The deal, announced on 15 December 2025 and now closed, involves a total consideration of 4.29 billion USD. This transaction is not merely a change of ownership but a structural move to take the target private. For the SME founder watching from the sidelines, the message is stark: if your science requires a decade to mature, the public equity route may no longer offer the patience or capital depth you need.

The deal mechanics here are instructive. The consideration structure combines immediate cash with an earn-out component. This is a critical detail for any founder navigating a sale. An earn-out introduces a specific commercial risk where future payouts depend on hitting targets set by the buyer. In a going-private scenario like this, the acquirer gains full control over strategic direction, which can make meeting those earn-out milestones difficult if the new owners decide to pivot the roadmap. We also note the regulatory context. As a US-to-US transaction in the healthcare sector, this deal would have faced scrutiny under US anti-trust thresholds, though the completion status suggests clearance was granted. The absence of a public prospectus means the usual FCA or SEC disclosure rules do not apply in the same way, but the fiduciary duties to shareholders remain paramount during the negotiation phase.

We believe this deal highlights a growing preference for buyers who can offer stability over the volatility of public trading. The mix of cash and contingent value reflects the buyer's caution while still offering upside if the science delivers. It is a pragmatic approach that balances immediate liquidity with future performance incentives. However, it places the onus on the selling founder to negotiate clear, achievable earn-out triggers. Vague targets or overly ambitious clinical milestones can easily turn a lucrative deal into a source of friction post-close.

Your immediate action this week should be to audit your own data room for any clinical or commercial milestones that could form the basis of an earn-out. If you are considering a sale, do not accept a standard template for contingent payments. Demand that every earn-out condition is tied to metrics you can directly influence and that are clearly defined in the contract before you sign.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More going private deals More from XOMA Royalty Corporation All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

28 July 2026CompletedHealthcare

CCP PAW 2 LIMITED to acquire ANIMALCARE GROUP PLC

CCP PAW 2 Limited has agreed to acquire Animalcare Group Plc in a going private transaction. The deal was announced and completed on 30 July 2026. Both the buyer and the…

Buyer: CCP PAW 2 LIMITED
Target: ANIMALCARE GROUP PLC
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United Kingdom deals

26 July 2026CompletedHealthcare

argenx BV to acquire Forte Biosciences, Inc.

argenx BV has agreed to acquire Forte Biosciences, Inc. in a going private transaction valued at USD 2.2 billion. The Belgian listed biotechnology company is purchasing…

Buyer: argenx BV
Target: Forte Biosciences, Inc.
Deal value: USD 2,200,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

6 July 2026CompletedHealthcare

Vertex Pharmaceuticals Incorporated to acquire Crinetics Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals, Inc. in a going private transaction valued at $10 billion. The deal, announced on 6…

Buyer: Vertex Pharmaceuticals Incorporated
Target: Crinetics Pharmaceuticals, Inc.
Deal value: USD 10,000,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

6 July 2026CompletedHealthcare

Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.

Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…

Buyer: Trafalgar Asset Management, LLC
Target: The Greater Cannabis Company, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 June 2026CompletedHealthcare

Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.

Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…

Buyer: Hanmi Pharmaceuticals Co. Ltd.
Target: Aptose Biosciences Inc.
Deal value: USD 3,466,470
Deal type: going private

Read deal Healthcare deals going private deals Canada deals

Buyer history